876170-40-0

Basic information

• Product Name: methyl 4-bromo-3-hydroxy-5-methoxybenzoate
• Synonyms: methyl 4-bromo-3-hydroxy-5-methoxybenzoate
• CAS NO: 876170-40-0
• Molecular Weight: 261.072
• Mol File: 876170-40-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: methyl 4-bromo-3-hydroxy-5-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-bromo-3-hydroxy-5-methoxybenzoate(876170-40-0)
• EPA Substance Registry System: methyl 4-bromo-3-hydroxy-5-methoxybenzoate(876170-40-0)

Safety Data

• Hazardous Substances Data: 876170-40-0(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 1041205-07-5 methyl 4-bromo-3-methoxy-5-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 16534-12-6 3,5-dihydroxy-4-bromobenzoic acid 

Downstream Products

• 1041205-08-6 methyl 4-bromo-3-ethoxy-5-methoxybenzoate 

Relevant articles and documents

Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY

Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).

SPIROCHROMANON DERIVATIVES

The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-b]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.